Summary & Overview
HCPCS Level II J9032: Injection, belinostat, 10 mg
HCPCS Level II code J9032 denotes the injection of belinostat, 10 mg, an intravenous oncology drug used in cancer treatment. This code is important nationally because it standardizes billing for belinostat administration across outpatient infusion centers and hospital outpatient departments, supporting consistent claims processing and payment for a specialized chemotherapy agent.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context about belinostat as an injectable oncology medication and practical billing information tied to HCPCS Level II reporting. The publication provides benchmarks where available, outlines common payer coverage considerations, and highlights policy and coding updates that affect billing for infused chemotherapeutic agents.
The document serves clinicians, billing professionals, and policy stakeholders by summarizing code meaning, typical sites of service, and the payer landscape for belinostat injections. It also points to areas where data is not available in the input, such as specific ICD-10 pairings, associated taxonomies, and related procedure or supply codes.
Billing Code Overview
HCPCS Level II code J9032 represents the injection of belinostat, 10 mg, an intravenous chemotherapeutic agent used in oncology care. The service type is an injectable oncology drug administration, and the typical site of service is an outpatient oncology infusion center or hospital outpatient department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory peripheral T-cell lymphoma receiving intravenous belinostat for systemic therapy. The patient presents to an outpatient oncology infusion center or hospital outpatient department for chemotherapy administration. Prior to treatment, the oncology nurse verifies the patient identity, reviews recent labs (complete blood count, liver function tests), confirms chemotherapy orders and premedications, and inspects the intravenous access (peripheral IV or implanted port). The pharmacist compounds J9032 (belinostat, 10 mg vial) under sterile conditions and documents lot numbers and expiration. The infusion nurse administers belinostat per protocol (dosage calculated by body surface area), monitors vital signs during the infusion, manages infusion-related adverse events, and documents start/stop times, lot numbers, and the exact quantity of drug billed in milligrams. Typical sites of service are an outpatient infusion center, hospital outpatient department, or ambulatory surgical center when part of combination chemotherapy. Relevant clinical workflow steps include order verification, chemotherapy safe‑handling and admixture, patient monitoring during infusion, and documentation for billing using J9032 with applicable modifiers for scenario-specific circumstances (e.g., drug wastage, provider ownership, or inpatient outpatient status).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |